NSABP FR-2
Select A Category

NSABP FR-2

A Phase II Study to Assess the Activity of PD-L1 Inhibition with Durvalumab (MEDI4736) after Chemo-Radiotherapy in Patients with Stage II-IV Microsatellite Stable (MSS) Rectal Cancer

Primary Objective: To document activity of durvalumab immediately following chemoRT in patients undergoing primary tumor surgery with stage II-IV MSS rectal cancer

Patient Population: patients with microsatellite stable (MSS) stages II-IV rectal cancer

Target Accrual: 47 patients

Status: recruiting participants

ClinicalTrials.gov Identifier: NCT03102047